A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin in children with growth hormone deficiency
Brief description of study
A randomised open-labelled two arm (somapacitan and Norditropin®) trial designed to compare the effect and safety of once weekly dosing of somapacitan with daily dosing of Norditropin® after 52 weeks in children with growth hormone deficiency followed by a 3 years single-arm extension period with once weekly dosing of somapacitan to evaluate safety.
Clinical Study Identifier: s19-00181
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
